ACCELERATED SENESCENCE OF BONE MARROW NUCLEATED ERYTHROCYTES IN MYELODYSPLASTIC SYNDROME

EHA Library, Mengyuan Liu, 419964

THE ROLE OF MDS-MSC DERIVED EXOSOMES IN REGULATION OF MDS CLONED CELL MALIGNANT PROLIFERATION THROUGH RN7SL1/RIG-I SIGNAL

EHA Library, JUAN GUO, 419965

GLOBAL ASSESSMENT OF THE MRNA DECAY DURING ERYTHROPOIESIS REVEALS ITS INVOLVEMENT IN NORMAL AND DEFECTIVE ERYTHROPOIESIS

EHA Library, Zubaidan Tuerdi, 419966

NOVEL THERAPEUTIC VULNERABILITIES IN DEL(5Q) MYELOID MALIGNANCIES

EHA Library, Sergio Martinez Høyer, 419967

COMPARATIVE ANALYSIS OF IMMUNE CELL DISTRIBUTION IN PERIPHERAL BLOOD AND BONE MARROW SAMPLES: CONTRASTING PATTERNS IN CONTROL SUBJECTS AND LOWER-RISK MYELODYSPLASTIC NEOPLASMS PATIENTS

EHA Library, Ioannis Kotsianidis, 419968

CIRCULAR RNA EXPRESSION IN MYELODYSPLASTIC SYNDROME HSPCS IS ASSOCIATED WITH THE EXPRESSION OF PROLIFERATION MARKERS AND RISK OF DISEASE PROGRESSION.

EHA Library, Eileen Wedge, 419969

MINIMAL RESIDUAL DISEASE IN CD34+ CELLS IN MYELODYSPLASTIC SYNDROME AFTER ALLOGENIC STEM CELL TRANSPLANTATION

EHA Library, Carolin Lindholm, 419970

GENOMIC EVOLUTION OF PATIENTS WITH MYELOID NEOPLASMS AND KNOWN ANTECEDENT CLONAL HEMATOPOIESIS

EHA Library, Kelly Chien, 419971

THE CLINICAL OUTCOME AND MOLECULAR SPECTRUM OF ASXL1 MUTATION IN MYELODYSPLASTIC SYNDROME

EHA Library, Juan Peng, 419972

CLINICAL EXPERIENCE WITH LUSPATERCEPT THERAPY IN LOW-RISK MYELODYSPLASTIC SYNDROMES WITH TRANSFUSION DEPENDENCY, POSITIVE EFFECT OF COMBINATION THERAPY WITH ERYTHROPOIETIN.

EHA Library, Anna Jonasova, 419973

EFFICACY AND PROGNOSTIC ASSESSMENT OF CHEMOTHERAPY-BRIDGED TRANSPLANTATION IN PEDIATRIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMESXINGCHEN

EHA Library, Xingchen Wang, 419974

UNDERSTANDING THE REAL-WORLD BURDEN OF LIVING WITH MYELODYSPLASTIC SYNDROME ACROSS THE EU5: DISCORDANCE BETWEEN PHYSICIAN AND PATIENT PERSPECTIVES

EHA Library, Katie Lewis, 419975

REAL WORLD OUTCOME OF THE FORMERLY KNOWN MDS-EB2 CATEGORY: ANALYSIS ACCORDING TO THE NEW 2022ICC/WHOCLASSIFICATIONS,IWG2023/ELN RESPONSE CRITERIA AND IPSS-M AND ELN PROGNOSTICS SYSTEMS.A GESMD STUDY

EHA Library, Sandra Castaño-Díez, 419976

OUTCOMES OF ORAL DECITABINE-CEDAZURIDINE USING A THREE- OR FIVE-DAY REGIMEN IN PATIENTS WITH MYELODYSPLASTIC OR OVERLAP SYNDROMES

EHA Library, Jonathan Hyak, 419977

IMPLEMENTATION OF OPTICAL GENOME MAPPING IN THE CYTOGENETICS DIAGNOSIS OF MYELODYSPLASTIC NEOPLASMS

EHA Library, Neus Torres Hernández, 419978

REFERRAL PATTERNS TO A SPECIALTY CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) CLINIC IN NEW YORK CITY

EHA Library, Sushruta Iruvanti, 419979

SERUM HYPOALBUMINEMIA IS AN INDEPENDENT PROGNOSTIC FACTOR IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Rami S. Komrokji, 419980

AZACITIDINE COMBINED WITH LUSPATERCEPT IN ELDERLY PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME: RESULTS OF AN OPEN-LABEL PROSPECTIVE MULTICENTER TRIAL IN CHINA

EHA Library, Hongju Yan, 419981

SPECTRUM AND CLINICAL IMPLICATIONS OF COHESIN MUTATIONS IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA)

EHA Library, Jessica M. Stempel, 419982

CLINICAL CHARACTERISTICS AND GENETIC LANDSCAPE OF A COHORT OF CHILDREN WITH MYELODYSPLASTIC NEOPLASMS FROM ARGENTINA

EHA Library, Maria Florencia Mininni, 419983

A PHASE I STUDY OF THE MYELOID CELL LEUKEMIA 1 (MCL1) INHIBITOR TAPOTOCLAX (AMG 176) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AFTER HYPOMETHYLATING AGENT FAILURE

EHA Library, Kelly Chien, 419984

EFFICACY/SAFETY OF LUSPATERCEPT FOR ANEMIA TREATMENT IN TRANSFUSION DEPENDENT (TD) LOWER-RISK (LR) MYELODYSPLASTIC SYNDROME WITH RING SIDEROBLASTS (MDS-RS): A PHASE 2 BRIDGING STUDY IN ASIAN PATIENTS

EHA Library, Zhijian Xiao, 419985

MODIFIED OGATA SCORE FOR THE DIAGNOSIS OF MYELOID DYSPLASIA IN A REAL-WORLD CLINICAL PRACTICE

EHA Library, Fiona O'Flynn, 419986

DISTINCT CLINICAL AND PROGNOSTIC FEATURES OF MYELODYSPLASTIC SYNDROME IN PATIENTS FROM THE MIDDLE EAST, NORTH AFRICA, AND BEYOND: A SYSTEMIC REVIEW

EHA Library, Amal Al-Haidose, 419987

BIOINFORMATICS ANALYSIS EXPLORES PATHOGENIC LINK BETWEEN AA AND MDS

EHA Library, Qinglin Hu, 419988

PERFORMANCE AND ACTIONABILITY OF GERMLINE GENETIC TESTING CRITERIA FOR PREDISPOSITION TO HEMATOLOGIC NEOPLASMS IN ADULTS

EHA Library, Sara Torres-Esquius, 419989

CLINICAL OUTCOMES OF PATIENTS WITH SETBP1 MUTATED MYELOID NEOPLASMS

EHA Library, Aref Al-Kali, 419990

STUDY ON THE CORRELATION BETWEEN BONE MARROW ADIPOCYTOKINES SUCH AS LEPTIN AND NAMPT AND MYELODYSPLASTIC NEOPLASMS

EHA Library, yuchun li, 419991

COMBINATION OF DECITABINE AND ETOPOSIDE IS HIGHLY EFFECTIVE IN TREATING P53-MUTATED MDS/AML

EHA Library, Jiexian Ma, 419992

CLINICAL IMPLICATIONS OF RAS PATHWAY MUTATIONS IN HIGHER RISK MYELODYSPLASTIC SYNDROMES/NEOPLASMS (MDS) TREATED WITH HYPOMETHYLATING AGENTS (HMA) - A MULTICENTER, RETROSPECTIVE ANALYSIS

EHA Library, Ted M. Getz, 419993

PROGNOSTIC SCORING SYSTEMS IPSS, IPSS-R AND IPSS-M HAD NO IDENTICAL PROGNOSTIC POWER DEPENDING ON TREATMENT IN MYELODYSPLASTIC SYNDROMES

EHA Library, Ghada Abichou, 419994

COMPARISON OF THE 2022 WORLD HEALTH ORGANIZATION CLASSIFICATION AND INTERNATIONAL CONSENSUS CLASSIFICATION IN MYELODYSPLASTIC SYNDROMES (MDS)

EHA Library, Yu-Sung Chang, 419995

LUSPATERCEPT UTILIZATION PATTERNS IN LOWER-RISK MYELODYSPLASTIC SYNDROME (LR-MDS): FINDINGS FROM A MULTINATIONAL MEDICAL RECORD REVIEW STUDY

EHA Library, María Díez Campelo, 419996

REAL-WORLD EXPERIENCE OF AZACITIDINE COMBINED WITH TISLELIZUMAB IN THE ELDERLY WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME.

EHA Library, Chen Yang, 419997

PROSPECTIVE ASSESSMENT OF RESPONSE IN A PHASE II TRIAL OF VENETOCLAX AND AZACITIDINE IN THERAPY-RELATED MDS WITH INTERNATIONAL WORKING GROUP 2006 AND 2023 CRITERIA FOR MYELODYSPLASTIC SYNDROMES

EHA Library, Kelly Pugh, 419998

THE ABILITY OF BLOOD SERUM TO SUPPORT THE PROLIFERATION OF BONE MARROW DERIVED MESENCHYMAL STROMAL CELLS IS REDUCED IN APLASTIC ANEMIA

EHA Library, Alena Dorofeeva, 419999

EXPLORING THE ROLE OF INTESTINAL FLORA IN THE PATHOGENESIS OF APLASTIC ANEMIA BASED ON INTEGRATED METABOLOMICS AND 16S RRNA SEQUENCING

EHA Library, Siyuan Cui, 420000

MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM THE BONE MARROW OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ARE AFFECTED DIFFERENTLY THAN CELLS OF PATIENTS WITH APLASTIC ANEMIA WITH PNH-CLONE

EHA Library, Alena Dorofeeva, 420001

TRANSFUSION AVOIDANCE WITH EPYSQLI™ (SB12), A BIOSIMILAR TO REFERENCE ECULIZUMAB: A POST-HOC ANALYSIS FROM THE PIVOTAL PHASE III STUDY.

EHA Library, Jun Ho Jang, 420003

REAL-WORLD EXPERIENCE OF PEGCETACOPLAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) WITH UNSATISFACTORY RESPONSE TO PREVIOUS THERAPEUTIC APPROACHES

EHA Library, Juan Carlos Vallejo Llamas, 420004

PATIENT EXPERIENCE OF IPTACOPAN IN THREE CLINICAL TRIALS FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

EHA Library, Carlos de Castro, 420005

CYCLOSPORINE PLUS AVATROMBOPAG VERSUS CYCLOSPORINE ALONE FOR FIRST-LINE TREATMENT OF ELDERLY PATIENTS WITH TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA: A SINGLE CENTER, RETROSPECTIVE STUDY

EHA Library, Zhuxin Zhang, 420006

EXPOSURE-RESPONSE MODELING USING POPULATION PK/PD METHODS RELIABLY PREDICT POPULATION AND INDIVIDUAL RESPONSES OF COMPLEMENT MATURE FACTOR D, HEMOGLOBIN AND LDH IN PNH PATIENTS EXPOSED TO OMS906

EHA Library, William Pullman, 420007

DECREASED REGULATORY T CELLS IN CHILDREN WITH AUTOIMMUNE NEUTROPENIA

EHA Library, KONSTANTINA TOUTOUDAKI, 420008

EFFICACY OF ROMIPLOSTIM IN NEWLY DIAGNOSED APLASTIC ANAEMIA

EHA Library, MADHUPRIYA B, 420009

UPFRONT MATCHED UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE IDIOPATHIC APLASTIC ANEMIA AND REFRACTORY CYTOPENIA OF CHILDHOOD IN PEDIATRIC PATIENTS. A STUDY OF THE SPANISH PEDIATRIC GROUP FOR HEMATOPOIETIC CELL TRANSPLANTATION AND CE

EHA Library, Luz Uría Oficialdegui, 420010

THE SILENT ROLE OF COPPER: HEMATOLOGICAL CONSEQUENCES OF ITS DEFICIENCY.

EHA Library, Magdalena María Gonzalez, 420011

THROMBOPOIETIN RECEPTOR AGONISTS FOR THE TREATMENT OF TRANSFUSION-DEPENDENT NON-SEVERE APLASTIC ANEMIA

EHA Library, Guangsheng He, 420012

CLINICAL PROFILE OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RECEIVING COMPLEMENT PROTEIN 5 INHIBITORS: RESULTS FROM A REAL-WORLD STUDY

EHA Library, Shreyans Gandhi, 420013

ISG15 CONFERS IXAZOMIB RESISTANCE OF MM CELLS BY SUPPRESSING CASP3/8-GSDMD DEPENDENT PYROPTOSIS

EHA Library, Hailong Tang, 420014

OPTICAL GENOME MAPPING UNVEILS CLINICALLY RELEVANT GENOMIC ALTERATIONS IN A COHORT OF PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Cristian Garcia-Ruiz, 420015

TOLERABILITY OF TREATMENTS IN MULTIPLE MYELOMA IN A REAL WORLD POPULATION: EXAMINING THE IMPACT OF ADVERSE EVENTS ON CLINICAL DECISION MAKING

EHA Library, Sandra Quinn, 420016

DISEASE SEVERITY AND ACCUMULATION OF END-STAGE DIFFERENTIATED CD8 TEMRA CELLS PREDICT SEVERE INFECTIONS IN MULTIPLE MYELOMA

EHA Library, Eva Tranter, 420017

TARGETING MYC IN MULTIPLE MYELOMA THROUGH SYNTHETIC LETHAL INTERACTIONS.

EHA Library, Sara Cristóbal Vargas, 420018

DISCOVERY OF NOVEL TARGETED DRUGS FOR K-RAS-MUTATED MYELOMA USING ISOGENIC K-RAS-MUTANT CELLS

EHA Library, Ichiro Hanamura, 420019

ROLE AND MECHANISM OF PIM-2 KINASE INHIBITOR-INDUCED IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 420020

CIRCRNA_0029614/MIR-335/RANKL AXIS REGULATES OSTEOCLAST DIFFERENTIATION TO AFFECT MULTIPLE MYELOMA OSTEOLYTIC LESIONS

EHA Library, xing cui, 420021

IGH TRANSLOCATIONS ARE MORE COMMON IN YOUNGER NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A REAL-WORLD STUDY BY THE NORDIC MYELOMA STUDY GROUP

EHA Library, Sigrún Thorsteinsdóttir, 420022

UNRAVELING SINGLE POINT VARIATIONS IN MULTIDRUG-RESISTANT MULTIPLE MYELOMA: IMPLICATIONS FOR TECLISTAMAB AND TALQUETAMAB RESISTANCE

EHA Library, Natalia Buenache Cuenda, 420023

EXOSOMAL LNCMALAT1 IS A NOVEL BIOMAKER FOR MULTIPLE MYELOMA ANGIOGENESIS

EHA Library, Xing Cui, 420024

DISPARITIES OF THE SEXES IN THE PREVALENCE AND CLINICAL CHARACTERISTICS OF MGUS; RESULTS FROM THE SCREENED POPULATION-BASED ISTOPMM STUDY

EHA Library, Anna Karen Richardson, 420025

NATURAL KILLER CELLS FROM PATIENTS RELAPSING DURING DARATUMUMAB THERAPY EXPRESS AN EXHAUSTED PHENOTYPE

EHA Library, Katrine Fladeland Iversen, 420026

EXPLORATORY ANALYSIS TO IDENTIFY RESPONSE-RELATED BIOMARKERS IN THE CHINA COHORT OF THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB FOR TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Hongmei Xu, 420027

CHARACTERIZATION OF THE BCMA EPITOPE BOUND BY BCMA-CD3 T CELL ENGAGER ELRANATAMAB.

EHA Library, Maria Josic, 420028

IDENTIFICATION AND VALIDATION OF FACTORS PROMOTING RESISTANCE TO CAR-T THERAPY IN MULTIPLE MYELOMA BY GENOME-WIDE CRISPR SCREENINGS

EHA Library, Paula Rodríguez-Márquez, 420029

THE ORPHAN NUCLEAR RECEPTOR NR5A2 REGULATES PHOSPHOLIPID REMODELING VIA MBOAT1 AND MBOAT2 TO PROMOTE PROLIFERATION AND DRUG RESISTANCE IN MULTIPLE MYELOMA CELLS

EHA Library, Panpan Li, 420030

RESOLVING CARFILZOMIB RESISTANCE MECHANISM IN MULTIPLE MYELOMA MODELS BY MUTI-OMICS ANALYSIS

EHA Library, Seungbin Han, 420031

M1A REGULATOR-MEDIATED METHYLATION MODIFICATION AND THEIR PROGNOSTIC VALUE IN MULTIPLE MYELOMA

EHA Library, Xing Cui, 420032

RADIOPSY: WB-MRI-ADC AND FAT FRACTION QUANTITATIVE FEATURES FOR DISCRIMINATION OF SMOLDERING AND MULTIPLE MYELOMA IN A PROSPECTIVE STUDY

EHA Library, Claudio Cerchione, 420033

DIVERSE MUTATIONAL CHARACTERISTICS OF PATIENTS WITH MULTIPLE MYELOMA SHOWING HIGH DIFFUSE LESIONS ON PET/CT

EHA Library, Hee Jeong Cho, 420034

MAP KINASE GENES MUTATIONS FOUND IN PAIRED TUMOR/CTDNA SAMPLES IN MULTIPLE MYELOMA.

EHA Library, Maiia Soloveva, 420035

ANALYSIS OF SINGLE-CELL TRANSCRIPTOMIC AND IMMUNE REPERTOIRE PROFILES REVEALS A SUPPRESSIVE IMMUNE MICROENVIRONMENT IN MULTI-DRUG-RESISTANT MULTIPLE MYELOMA

EHA Library, Yutong Wang, 420036

HIGH TRANSCRIPT LEVELS OF KCNN3 IN MULTIPLE MYELOMA AND CORRELATED WITH CYTOGENETIC ABNORMALITIES AND POOR PROGNOSIS

EHA Library, Nan Yan, 420037

LIQUID BIOPSY FOR COMPLETE RESPONSE MULTIPLE MYELOMA PATIENT MONITORING BASED ON PAIRED ANALYSIS OF FLOW CIRCULATING TUMOUR PLASMA CELLS AND MONOCLONAL IMMUNOGLOBULIN BY MALDI-TOF MASS SPECTROMETRY

EHA Library, Luzalba Sanoja-Flores, 420038

ESTABLISHING A ROBUST MOUSE MODEL FOR STUDYING MULTIPLE MYELOMA BONE DISEASE

EHA Library, Melika Bakharzi, 420039

EXPLORING SYNERGISTIC EFFECTS OF COMBINED DARATUMUMAB AND BELANTAMAB MAFODOTIN THERAPY IN MULTIPLE MYELOMA

EHA Library, Mauro Lorenzo-Mohamed, 420040

MULTIPLE MYELOMA CAUSES CHANGES IN FATTY ACID METABOLISM IN TUMOUR ASSOCIATED MACROPHAGES VIA A FATP2 DEPENDENT MECHANISM

EHA Library, Rosie Taylor, 420041

REFRACTORY CYTOPENIAS AND SECONDARY MYELOID NEOPLASMS IN MULTIPLE MYELOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANT AND LENALIDOMIDE MAINTENANCE THERAPY – A REAL-WORLD STUDY

EHA Library, David Martínez, 420042

UMA PANEL: AN NGS APPROACH TO DEFINE THE MOLECULAR PROFILE OF MULTIPLE MYELOMA PATIENTS. RESULTS OF INTRA- AND INTER-LABORATORY VALIDATION EXPERIMENTS.

EHA Library, BARBARA TAURISANO, 420043

SOLUBLE BCMA AND BCMA-CONTENT IN CIRCULATING EXTRACELLULAR VESICLES TO EVALUATE RESPONSE IN MULTIPLE MYELOMA RECEIVING BCMA-DIRECTED CARTS

EHA Library, Bárbara Castellanos, 420044

IDENTIFYING IMMUNE CHECKPOINTS ON DYSREGULATED T-CELLS AS PROGNOSTIC BIOMARKERS FOR MULTIPLE MYELOMA PATIENTS WITH COVID-19

EHA Library, Junling Zhuang, 420045

THE ROLE OF BISPECIFIC ANTIBODIES AND CAR T CELLS IN THE TREATMENT OF MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

EHA Library, Julia Mersi, 420046

EFFICACY AND SAFETY OF TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE PHASE 1/2 MONUMENTAL-1 STUDY

EHA Library, Jie Jin, 420047

REAL-WORLD CHARACTERISTICS AND OUTCOMES FOR LENALIDOMIDE-REFRACTORY PATIENTS WITH MULTIPLE MYELOMA RECEIVING DARATUMUMAB–BORTEZOMIB–DEXAMETHASONE AS SECOND-LINE TREATMENT IN ENGLAND

EHA Library, Sally Moore, 420048

EFFECT OF DENOSUMAB ON PROGRESSION-FREE SURVIVAL AND BONE HEALTH IN PATIENTS WITH MULTIPLE MYELOMA: A MULTICENTER PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Bin Chu, 420049

PERCUTANEOUS VERTEBROPLASTY/KYPHOPLASTY CONTRIBUTES TO THE IMPROVED OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A SINGLE-CENTER COHORT STUDY.

EHA Library, Fujing Zhang, 420050

EVALUATION OF CHROMOSOMAL ABNORMALITIES AND OUTCOME IN A REAL WORLD POPULATION OF MYELOMA PATIENTS TREATED OVER 10 YEARS.

EHA Library, Thomas Creasey, 420051

EFFECTIVENESS OF AN ONLINE CONTINUING MEDICAL EDUCATION CURRICULUM TO IMPROVE HEMATOLOGISTS/ONCOLOGISTS’ ABILITY TO MANAGE MULTIPLE MYELOMA

EHA Library, Sarah Elizabeth Bomba, 420052

VALIDATION OF THE IMPEDE VTE SCORE FOR PREDICTION OF VENOUS THROMBOEMBOLISM IN CHINESE PATIENTS WITH MULTIPLE MYELOMA: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY

EHA Library, Lijuan Fang, 420053

CARDIOVASCULAR TOXICITY AFTER CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE COMBINATION CHEMOTHERAPY IN THE REAL-WORLD ASIAN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Ji Hyun Lee, 420054

COULD CLINICAL-LABORATORY FEATURES RECOGNIZE FUNCTIONAL HIGH RISK MULTIPLE MYELOMA PATIENTS? A REAL-WORLD ANALYSIS

EHA Library, Sonia Morè, 420055

IN-CLASS TRANSITION FROM PARENTERAL BORTEZOMIB (V) TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF US MM-6 OVERALL AND BY PATIENT (PT) SUBGROUPS OF INTEREST

EHA Library, Ralph Boccia, 420056

INDIRECT TREATMENT COMPARISONS OF DARATUMUMAB-POMALIDOMIDE-DEXAMETHASONE (DPD) AND POMALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (PVD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Wee Joo Chng, 420057

REAL WORLD ASSESSMENT: EARLY BEST RESPONSE AS A HARBINGER OF POOR PROGNOSIS IN NEWLY DIAGNOSIS MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS

EHA Library, JIE SHI, 420058

MULTIPLE MYELOMA IN THE YOUNG: INSIGHTS ON PROGNOSIS, CLINICAL FEATURES AND TREATMENT OUTCOME DERIVED FROM NATIONALWIDE GERMAN REGISTRY DATA AND A NESTED MULTICENTER SAMPLE

EHA Library, Abdulaziz Kamili, 420059

REAL-WORLD OBSERVATIONS ON THE EVOLVING TREATMENT LANDSCAPE AND IMPROVED SURVIVAL OUTCOMES FOR MULTIPLE MYELOMA PATIENTS IN FINLAND

EHA Library, Marika Waltari, 420060

THE VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN PREDICTING THE PROGNOSIS OF NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Zhaoyun Liu, 420061

ZANUBRUTINIB IN MONOCLONAL IMMUNOGLOBULIN M-RELATED LIGHT CHAIN AMYLOIDOSIS: TOLERABILITY AND EFFICACY

EHA Library, Wouter Verhaar, 420062

UPDATED RESULTS OF A MATCHING-ADJUSTED INDIRECT COMPARISON OF ELRANATAMAB VERSUS TECLISTAMAB IN PATIENTS WITH TRIPLE-CLASS EXPOSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Patrick Hlavacek, 420064

PATIENT-REPORTED OUTCOMES FROM THE RANDOMIZED PHASE 3 CANOVA STUDY OF VENETOCLAX-DEXAMETHASONE VS POMALIDOMIDE-DEXAMETHASONE IN PATIENTS WITH T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 420065